CurrentBlue Cross Blue Shield - South DakotaPolicy 02.01.82

High Intensity Laser Therapy

This policy governs the medical policy determination for use of high-intensity (Class IV) laser therapy for chronic musculoskeletal pain, Bell's palsy, and other indications in Blue Cross Blue Shield - South Dakota members.

Policy Summary

PayerBlue Cross Blue Shield - South Dakota

PolicyHigh Intensity Laser Therapy

Policy CodePolicy 02.01.82

Change TypeAnnual review — no material changes

Effective DateAug 1, 2024

Next Review DateAug 1, 2025

Key ActionDocument rationale, prior conservative treatments tried, and clinical status when submitting requests for HILT.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Class IV (>500 mW)Device threshold

Insufficient evidenceChronic pain coverage

Insufficient evidenceBell's palsy coverage

20 SRsSystematic reviews

MD -2.04 VASLargest pain MD

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determination and Evidence Summary

Not covered — investigational

Coverage stance for HILT

Investigational indications: HILT is considered investigational for treatment of chronic musculoskeletal pain, Bell's palsy, and all other indications.

Evidence insufficient to determine improvement in net health outcome based on randomized trials and systematic reviews with methodological limitations and heterogeneity.

Chronic musculoskeletal pain — evidence synthesis

Evidence summary and applicability

Evidence: Systematic reviews and randomized trials report statistically and sometimes clinically significant improvements in pain and function for some musculoskeletal conditions with HILT, but confidence is reduced by serious methodological limitations and variable SR quality (AMSTAR-2 ratings low or critically low).

Heterogeneity in study protocols, cointerventions, and patient characteristics reduces applicability.

Conditions with reported benefit: Reported benefits in some reviews/meta-analyses include frozen shoulder, knee osteoarthritis, low back pain, myofascial pain, neck pain

Effect sizes and direction vary across reviews; some outcomes show large SMDs for neck and low back pain.

Limitations: Trials commonly have small samples, high risk of bias (lack of blinding, allocation issues), short follow-up, and inconsistent HILT parameters and dosing

These limitations preclude firm conclusions about effectiveness.

Bell's palsy — clinical context

HILT as alternative therapy for Bell's palsy

Population: Individuals with Bell's palsy (acute unilateral facial weakness or paralysis).

Intervention: High-intensity laser therapy (HILT).

Comparator: Standard care including conservative therapy (e.g., facial exercise) and medications such as corticosteroids and antivirals.

Outcomes: Improvement in functional outcomes and quality of life measured by Facial Disability Index and House-Brackmann Scale; effects expected over weeks to months.

Evidence limitations for Bell's palsy and general HILT effectiveness

Evidence summary and implication

Bell's palsy RCT evidence: One randomized trial (N=48) compared HILT, low-level laser, and exercise; both laser groups improved more than exercise with greatest improvement in HILT, but methodological limitations and natural recovery of Bell's palsy limit attribution of effect to HILT.

Limitations include lack of blinding, no intention-to-treat analysis, and short follow-up; natural resolution of Bell's palsy complicates interpretation.

Summary of pooled evidence

Systematic review and meta-analysis findings (umbrella review)

Meta-analyses summarized: Multiple systematic reviews and meta-analyses report variable effects of HILT on pain and disability across conditions; pooled estimates (MD or SMD) show statistically significant effects in some analyses but heterogeneity and frequently unreported or low GRADE ratings limit confidence.

Appendix 1 summarizes multiple meta-analyses with I2 values ranging widely and GRADE often NR/low/very low.

The policy does not list any indications for which High Intensity Laser Therapy (HILT) is considered routinely covered. HILT is considered investigational for chronic musculoskeletal pain, Bell's palsy, and all other indications, because the evidence is insufficient to determine that the technology improves net health outcomes.

Randomized controlled trials and multiple systematic reviews report some statistically and clinically significant improvements in pain and function with HILT for certain musculoskeletal conditions, but serious methodological limitations and substantial heterogeneity in device parameters, cointerventions, and patient characteristics reduce confidence in the findings. Consequently, current evidence is insufficient to demonstrate a net health benefit for routine use of HILT.

Although some reviews report benefit for specific musculoskeletal conditions, there are no established practice guidelines defining HILT's role in chronic pain care pathways. The policy notes the relevant population is individuals who have not responded to conservative therapy (e.g., exercise, physical therapy, NSAIDs), but even in that context, routine coverage is not supported given the low-to-moderate certainty evidence, heterogeneous protocols, and trial limitations.

For Bell's palsy the available randomized evidence is limited to a single small RCT that reported greater short‑term improvement with HILT versus exercise, but study design limitations and the condition's frequent spontaneous recovery make attribution of benefit to HILT uncertain. Therefore, evidence is insufficient to determine an improvement in net health outcome for Bell's palsy.

The provided excerpts do not contain any explicit statements designating HILT as covered for particular indications; instead, the appendix and meta-analytic summaries present evidence only and do not by themselves establish coverage or exclusion rules.

Appendix materials present pooled results from systematic reviews and meta-analyses to inform policy assessment but do not define coverage criteria. These evidence summaries are presented for review and do not by themselves establish coverage or exclusion determinations.

The appendix excerpts summarize outcomes, heterogeneity, and GRADE ratings from multiple reviews but do not state explicit coverage exclusions. They are intended to inform the policy evaluation rather than to declare services not medically necessary.

Within the provided excerpts there are no conditions specifically labeled as not medically necessary; the appendix reports meta-analytic findings and heterogeneity metrics but does not itself designate any services as not medically necessary.

This portion of the appendix reports pooled effect estimates and heterogeneity (I2) across reviews but does not assert that any services are not medically necessary; it summarizes evidence to support policy deliberations.

The appendix provides definitions, outcome measures, and a note that heterogeneity is assessed by the I2 statistic, but it does not itself declare services as not medically necessary; its role is to supply evidence details for policy determination.

Billing and Coding

Codes that may be utilized for HILTCPT | mixed

17999	Unlisted procedures, skin, mucous membrane and subcutaneous tissue (may be utilized for high-intensity laser therapy: Diowave Laser System, ESPT-3X, K-Laser, LCT-1000, OptonPro).
97039	Unlisted modality (specify type of time if constant attendance) (may be utilized for high-intensity laser therapy: Diowave Laser System, ESPT-3X, K-Laser, LCT-1000, OptonPro).
97139	Unlisted therapeutic procedure (specify) (may be utilized for high-intensity laser therapy: Diowave Laser System, ESPT-3X, K-Laser, LCT-1000, OptonPro).
99199	Unlisted special service, procedure or report (may be utilized for high-intensity laser therapy: Diowave Laser System, ESPT-3X, K-Laser, LCT-1000, OptonPro).

See Codes tablemixed

No codes listed

inv-20: Device power output threshold — Class IV (>500 mW)

Device classClass IV therapeutic non-surgical laser device

Power output threshold>500 mW

Intended tissue penetrationCapable of transmitting energy beyond the skin to deep musculoskeletal tissues

inv-21: Heterogeneity (I2) — interpretive threshold note

I2 interpretive guidance>40% indicates substantial heterogeneity

Heterogeneity implicationHigh I2 reduces confidence in pooled estimates and may limit applicability to clinical protocols

Prior Authorization, Documentation, and Billing Guidance

Denial Risk

Denial risk and administrative expectations

High Intensity Laser Therapy (HILT) is designated investigational in this policy; evidence limitations and methodological concerns have led to insufficient confidence in effectiveness and may result in coverage denials.

Evidence limitations (small RCTs, methodological flaws, heterogeneity of HILT parameters, limited follow-up) may trigger medical necessity or coverage denials.
No explicit prior authorization or administrative prior approval requirement is stated in this policy (Prior Approval: Not applicable).
No specific documentation requirements or administrative rules for HILT are described in the policy excerpts or appendix.
Appendix 1 provides pooled outcome statistics and GRADE/quality ratings from systematic reviews and umbrella reviews that informed the policy.
There are no described step therapy or sequencing requirements, and no explicit conservative-treatment sequencing beyond the general expectation that HILT would be considered for individuals who have not responded to conservative therapies.

Prior Conservative Care and Documentation

Documented failure of conservative therapy is implied as intended population but policy considers HILT investigational regardless

Conservative therapy context and policy implication

Intended population: Individuals with chronic musculoskeletal pain who have not responded to conservative treatment (e.g., self-care, physical therapy, NSAIDs).

Policy background references this population but HILT is considered investigational regardless of prior conservative therapy.

Prior conservative therapy recommended (no explicit node details provided)

Prior conservative therapy is recommended though policy remains investigational

Recommendation: Consider prior trials of standard conservative care (exercise, physical therapy, medications; for Bell's palsy include corticosteroids and antivirals) before considering advanced modalities.

This is a recommended documentation expectation; it does not change investigational stance.

Definitions and Background

inv-47: High-intensity laser therapy (HILT) — Class IV definition (>500 mW)

DefinitionHigh-intensity laser therapy (HILT) is a Class IV therapeutic non-surgical laser device with power output >500 mW

Mechanism overviewEmits infrared energy to provide topical heat, photobiomodulation, photothermal effects, and proposed analgesic/neural inhibition effects

Clinical settingProposed for office-based use to treat musculoskeletal disorders and Bell's palsy

inv-48: HILT therapeutic intervention under review

Intervention under reviewHigh Intensity Laser Therapy (HILT)

Therapy descriptionApplication of high-power laser for analgesia, tissue healing, and functional improvement

Treatment Frequency and Imaging Requirements

inv-62: High Intensity Laser Therapy — frequency limits (placeholder)

Frequency limits presentNo specific frequency limits specified in policy text (placeholder)

Policy stancePolicy lists HILT under investigational; no routine frequency guidelines provided

Recommendation for documentationIf billed, provide procedure details when using unlisted codes; frequency should align with studied protocols if used as justification

inv-63: HILT — frequency limits (appendix reference)

Appendix referenceAppendix summarizes multiple meta-analyses but does not specify standardized treatment frequency limits for HILT

Heterogeneity noteReported I2 varies widely across meta-analyses (0%–96%), reflecting diverse protocols including frequency

Not Covered / Investigational Services

Overall policy conclusion: Use of HILT is considered investigational because current randomized trials and systematic reviews have methodological limitations and heterogeneous protocols, and the evidence is insufficient to demonstrate improved net health outcomes for chronic musculoskeletal pain and Bell's palsy.

Policy Summary

PayerBlue Cross Blue Shield - South Dakota

PolicyHigh Intensity Laser Therapy

Policy CodePolicy 02.01.82

Change TypeAnnual review — no material changes

Effective DateAug 1, 2024

Next Review DateAug 1, 2025

Key ActionDocument rationale, prior conservative treatments tried, and clinical status when submitting requests for HILT.

SourceLink

On This Page

Use in assessmentReport I2 with pooled results and consider subgroup or sensitivity analyses when I2 is elevated

Documentation Required

Documentation expectations (recommended)

When submitting requests or clinical information related to HILT, include documentation of the diagnosis, prior conservative treatments tried, rationale for HILT, baseline and follow-up functional outcome measures when available, and any supporting evidence. Because the policy classifies HILT as investigational, high-quality evidence or new data may be needed to support coverage.

Document prior conservative care (e.g., exercise, physical therapy, NSAIDs, corticosteroid/antiviral therapy for Bell's palsy) and duration/failure of those treatments.
Provide baseline and follow-up outcomes (e.g., pain scores, Facial Disability Index, House-Brackmann Scale, functional measures) and timing of assessments.
If submitting new clinical evidence or trial results, follow Wellmark submission process (address in Appendix 1 contact information).

Billing Rule

Billing / coding guidance

Billing for HILT is commonly reported with unlisted or modality codes; providers should confirm coding and may need to supply supporting documentation when using unlisted codes.

Potential codes that may be used: 17999 (unlisted procedure), 97039 (unlisted modality, constant attendance), 97139 (unlisted therapeutic procedure), 99199 (unlisted special service).
Include procedure description, device used (e.g., Diowave, ESPT-3X, K-Laser, LCT-1000, OptonPro), number of units/time, and clinical rationale when billing unlisted codes.

Prior Authorization

Prior authorization and step-therapy status

Policy and appendix excerpts do not specify prior authorization, step therapy, or detailed administrative requirements for HILT. Providers should verify member benefits and any local plan-specific prior authorization rules before scheduling services.

Prior approval: Not applicable in this policy excerpt — however, some plans or networks may require prior authorization for unlisted procedures or services billed with the codes above.
Step therapy: No step therapy or formal sequencing requirements are described in the policy or appendix.
Administrative requirements: No explicit administrative documentation checklist or prior authorization form is provided in these excerpts.

Document prior conservative therapy and rationale for HILT use

Documentation expectations for prior therapy and rationale

Documentation required: Document prior conservative treatments attempted and clinical rationale for use of HILT when submitting evidence or authorization requests.

Include specifics of conservative care (type, duration, response) and why HILT is being considered despite investigational status.

Conservative treatment requirements — not detailed in provided appendix

Conservative treatment requirements — appendix excerpt

Appendix detail: No specific conservative treatment prerequisites are detailed in the provided appendix tables summarizing systematic reviews and meta-analyses.

Appendix focuses on pooled outcomes and methodological quality rather than operational treatment sequencing.

No conservative-treatment prerequisites described in appendix excerpt

Conservative-treatment prerequisites not specified

No prerequisites described: The appendix excerpt does not describe conservative-treatment prerequisites prior to HILT in the summarized reviews.

Policy materials note intended population as non-responders to conservative care, but the appendix provides evidence summaries only.

Conservative treatment requirements — no nodes provided in appendix

Conservative treatment requirements — absence of operational nodes

Operational guidance: No operative criteria or discrete 'must-try' conservative therapy nodes are provided in the appendix; clinical documentation expectations are recommended elsewhere in the policy.

Providers should document prior care per general documentation guidance but no explicit checklist is provided in appendix excerpts.

Comparators in trialsPlacebo/sham, low-level laser therapy (LLLT), conventional physical therapy or exercise

inv-49: Bell's palsy — definition (acute unilateral facial weakness)

Clinical definitionAcute unilateral facial muscle weakness or paralysis due to dysfunction of the seventh cranial nerve

Typical courseOften improves over weeks to months, complicating attribution of benefit to interventions

Population of interestIndividuals diagnosed with Bell's palsy

inv-50: Outcomes measures — Facial Disability Index and House-Brackmann Scale

Facial Disability Index (FDI)Patient-reported measure used to assess functional impact of facial palsy; used in HILT trials

House-Brackmann ScaleClinician-rated scale to grade severity of facial nerve dysfunction; used as an outcome in HILT studies

Timing of assessmentOutcomes in cited trials assessed at 3 to 6 weeks and over longer follow-up for healing effects

inv-51: HILT as evaluated in RCT comparisons to placebo, LLLT, conventional care

RCT comparisonsRandomized trial (Alayat et al) compared HILT, low-level laser therapy, and exercise; both laser groups improved more than exercise, with greatest improvement for HILT

Trial limitationsLack of blinding, no intention-to-treat analysis, and short follow-up limit confidence in attribution of benefit

Treatment protocol in RCTLaser treatment given 3 times/week to 8 points on affected side for 6 weeks; outcomes at 3 and 6 weeks

inv-52: High Intensity Laser Therapy (alternate label)

Alternate labelHigh Intensity Laser Therapy (HILT)

AbbreviationHILT

Related modalityOften contrasted with low-level laser therapy (LLLT) in evidence summaries

inv-53: PI — Pain intensity (VAS) definition

DefinitionPain intensity (PI) is commonly measured by visual analogue scale (VAS) or numeric pain rating scales in HILT studies

Use in trialsPI at rest or during activity is a frequent primary outcome in pooled meta-analyses

ReportingResults reported as mean difference (MD) on VAS or standardized mean difference (SMD) across reviews

inv-54: LLLT — Low-level laser therapy definition

DefinitionLow-level laser therapy (LLLT) is a lower-power laser modality used in trials and compared with HILT

Relation to HILTLLLT is frequently a comparator in RCTs evaluating HILT effectiveness

AbbreviationLLLT

inv-55: GRADE — quality of evidence framework

FrameworkGRADE = Grading of Recommendations, Assessment, Development, and Evaluations (quality of evidence)

Use in reviewsGRADE ratings reported or noted as NR/low/very low across many systematic reviews of HILT

ImplicationLow/very low GRADE reduces confidence in pooled effect estimates and policy conclusions

High‑intensity laser therapy (HILT) refers to Class IV therapeutic non‑surgical lasers with power output >500 mW intended to transmit energy to deeper musculoskeletal tissues. Proposed mechanisms include photobiomodulation, photothermal effects, and possible neural inhibition or endorphin release, with the goal of reducing pain and promoting local circulation; however, these mechanisms are not well established in clinical trials and device parameters vary widely across studies.

Implication for billingAbsence of appendix-specified frequency limits means frequency should be justified by trial protocols if used clinically

inv-64: HILT — frequency limits (appendix reference)

Appendix pooled resultsUmbrella review entries list trials with varying schedules; no uniform frequency limits provided in appendix summaries

Evidence variabilityLarge between-study heterogeneity (I2 often ≥70%) indicates inconsistent dosing/frequency across trials

Practical noteWhen citing evidence for frequency, reference the specific RCT/meta-analysis protocol used to support the schedule

Note

Imaging requirements — none specified

No imaging requirements for HILT are specified in the policy excerpts or appendix.

Standard imaging considerations for underlying musculoskeletal conditions are discussed for comparators, but no HILT‑specific imaging rules are stated.

Note

Imaging requirements — not specified

The document does not specify imaging prerequisites for HILT in the provided sections.

Note

Imaging requirements — HILT (no imaging stated)

No imaging requirements are described for HILT in the appendix or policy excerpts.

Note

Imaging requirements — not specified in excerpt

Imaging requirements are not specified in the provided excerpted material.